About 30 results found for searched term "NL-1" (0.045 seconds)
| Cat.No. | Name | Target |
|---|---|---|
| M2568 | IDO-IN-2 (NLG-919 Analogue) | IDO |
| GDC-0919 analogue | ||
| NLG919 is a potent IDO (indoleamine-(2,3)-dioxygenase) pathway inhibitor with Ki/EC50 of 7 nM/75 nM. | ||
| M5004 | Kevetrin hydrochloride | p53 |
| UNII-NL6L2371DP | ||
| Kevetrin hydrochloride is a small molecule and activator of the tumor suppressor protein p53, with potential antineoplastic activity. | ||
| M8560 | Anle138b | Amyloid |
| Anle138b is a fluorescent inhibitor of α-synuclein and prion-protein (PrPSc) aggregation that reduces the progression of prion and Parkinson′s disease in animal models. | ||
| M9085 | Indoximod | IDO |
| NLG-8189; D1MT; 1-methyl-D-tryptophan | ||
| Indoximod, also known as NLG8189 and D-1MT is an indoleamine 2,3-dioxygenase (IDO) pathway inhibitor with a Ki value of 19 μM. | ||
| M10302 | 1-Methyl-L-tryptophan | IDO |
| (S)-Indoximod; (S)-NLG-8189 | ||
| 1-Methyl-L-tryptophan is an inhibitor of indoleamine 2,3-dioxygenase (IDO). | ||
| M10608 | NLX-101 (F-15599) | 5-HT Receptor |
| NLX101 | ||
| NLX-101 (F-15599) is a highly selective G-protein biased 5-HT1A receptor agonist, with Ki of 3.4 nM. NLX-101 (F-15599) mediates antidepressant-like activity in rats via prefrontal cortex 5-HT 1A receptors. NLX-101 (F-15599) has over 1000-fold higher affinity for this target over other receptors. | ||
| M11187 | Eclitasertib | RIPK |
| DNL-758; SAR-443122 | ||
| Eclitasertib (DNL-758) is a receptor interaction protein kinase 1 (RIPK1) inhibitor, with IC50 value of <1 μΜ. | ||
| M11556 | NLG-919 (Navoximod) | IDO |
| Navoximod; GDC-0919; IDO-IN-7; NLG-1488 | ||
| Navoximod (GDC-0919; Nlg-919) is an effective IDO (indoleamine-(2,3)-dioxygenase) inhibitor with Ki/EC50 of 7 nM/75 nM respectively. | ||
| M13383 | (Rac)-Indoximod | IDO |
| 1-Methyl-DL-tryptophan; (Rac)-NLG-8189 | ||
| (Rac)-Indoximod(1-methyl-DL-tryptophan) is an indoleamine 2, 3-dioxygenase (IDO) inhibitor. | ||
| M21474 | Nln activator 1 | Others |
| Nln activator 1 is a first-in-class peptide neurolysin activator with enhanced brain permeability and stability. | ||
| M28284 | [Lys5,MeLeu9,Nle10]-NKA(4-10) | Neurokinin Receptor |
| [Lys5,MeLeu9,Nle10]-NKA(4-10) is a highly selective and potent NK2 receptor agonist, with an IC50 of 6.1 nM. | ||
| M29177 | Befiradol | 5-HT Receptor |
| NLX-112; F13640 | ||
| Befiradol (NLX-112) is a selective 5-HT1A receptor agonist. | ||
| M29639 | Befiradol hydrochloride | 5-HT Receptor |
| NLX-112 hydrochloride; F 13640 hydrochloride | ||
| Befiradol hydrochloride (NLX-112 hydrochloride) is a selective 5-HT1A receptor agonist. | ||
| M31035 | [Lys5,MeLeu9,Nle10]-NKA(4-10) TFA | Neurokinin Receptor |
| [Lys5,MeLeu9,Nle10]-NKA(4-10) TFA is a highly selective and potent NK2 receptor agonist, with an IC50 of 6.1 nM. | ||
| M42016 | NLRP3-IN-17 | NLR |
| NLRP3-IN-17 is a potent, selective and orally active NLRP3 inflammasome inhibitor with an IC50 value of 7 nM. | ||
| M42022 | NLRP3-IN-19 | NLR |
| NLRP3-IN-19 (JT001) is a potent, specific and orally active inhibitor of NLRP3. | ||
| M42023 | NLRP3-IN-19 sodium | NLR |
| NLRP3-IN-19 (JT001) is a potent, specific and orally active inhibitor of NLRP3. | ||
| M42025 | NLRP3-IN-18 | NLR |
| NLRP3-IN-18 is a potent NLRP3 inhibitor with an IC50 value of ≤1.0 µM. | ||
| M49926 | DNL104 | RIPK |
| DNL104 is a RIPK1 inhibitor that can be used in Alzheimer's disease related studies. | ||
| M51454 | [Thr28, Nle31]-Cholecystokinin (25-33), sulfated | Others |
| [Thr28, Nle31]-Cholecystokinin (25-33) is a biological active peptide. | ||
| M51456 | (Nle8, 18, Tyr34)-pTH (1-34) (human) | Others |
| (Nle8,18,Tyr34)-pTH (1-34) (human) is a polypeptide that can be found by peptide screening. | ||
| M51473 | (Phe2, Nle4)-ACTH (1-24) (human, bovine, rat) | Others |
| (Phe2,Nle4)-ACTH (1-24) (human, bovine, rat) is a fragment of the ACTH hormone. | ||
| M52895 | [Nle8] Somatostatin (1-28) | Somatostatin Receptor |
| [Nle8] Somatostatin (1-28) is a derivative of somatosttin (1-28) with norleucine replacing methionine in position 8. | ||
| M53052 | (D-Pro2, D-Trp6, 8, Nle10)-Neurokinin B | Neurokinin Receptor |
| (D-Pro2,D-Trp6,8,Nle10)-Neurokinin B is a competitive antagonist of Neurokinin B (Neurokinin Receptor) with a pA2 of 5.5. | ||
| M53056 | [Lys5, MeLeu9, Nle10]Neurokinin A(4-10) | Neurokinin Receptor |
| [Lys5,MeLeu9,Nle10]Neurokinin A(4-10) (LMN-NKA), an analogue of Neurokinin A, is a selective and potent NK2R agonist. | ||
| M53058 | [Nle11]-Substance P | Neurokinin Receptor |
| [Nle11]-Substance P is a substance P analog that avoids methionine oxidation problems. | ||
| M53060 | [Tyr8, Nle11] Substance P | Neurokinin Receptor |
| [Tyr8,Nle11] Substance P is a Substance P analog. | ||
| M53072 | [D-Pro4, D-Trp7, 9, Nle11] Substance P (4-11) | Neurokinin Receptor |
| [D-Pro4,D-Trp7,9,Nle11] Substance P (4-11) is a potent neurokinin NK1 antagonist. | ||
| M53073 | [Nle13]-Motilin | Others |
| [Nle13]-Motilin, a motilin analogue, is a motilin receptor agonist. | ||
| M53165 | [His1, Nle27] GHRF (1-32), amide, human | Ghrelin Receptor/GHSR |
| [His1,Nle27] GHRF (1-32), amide, human is a Growth hormone releasing hormone (GHRH) analog. | ||
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
